Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000, C514S444000
Reexamination Certificate
active
07928128
ABSTRACT:
(R)-(−)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is useful for treatment of adverse effects in treating Parkinson's disease.
REFERENCES:
patent: 4438119 (1984-03-01), Allen et al.
patent: 4981695 (1991-01-01), Appelgren et al.
patent: 5137901 (1992-08-01), Junge et al.
patent: 5141930 (1992-08-01), Nakao
patent: 5314888 (1994-05-01), Dodman et al.
patent: 5318988 (1994-06-01), Schohe-Loop et al.
patent: 5468882 (1995-11-01), Schohe-Loop et al.
patent: 5502080 (1996-03-01), Hitzig
patent: 5541199 (1996-07-01), Mewshaw et al.
patent: 5670667 (1997-09-01), Mewshaw et al.
patent: 5756521 (1998-05-01), Mewshaw et al.
patent: 5762960 (1998-06-01), Dodman
patent: 5767132 (1998-06-01), Boettcher et al.
patent: 5935973 (1999-08-01), Birch et al.
patent: 6114334 (2000-09-01), Kerrigan et al.
patent: 6214829 (2001-04-01), Feenstra et al.
patent: 6235774 (2001-05-01), Fahrig et al.
patent: 6242456 (2001-06-01), Dodman et al.
patent: 2003/0181486 (2003-09-01), Bartoszyk et al.
patent: 2364685 (1975-07-01), None
patent: 4135474 (1993-04-01), None
patent: 4226527 (1994-02-01), None
patent: 196 48 384 (1998-05-01), None
patent: 19648384 (1998-05-01), None
patent: 0145067 (1985-06-01), None
patent: 0465254 (1992-01-01), None
patent: 0 707 007 (1996-04-01), None
patent: 0707007 (1996-04-01), None
patent: 0900792 (1999-03-01), None
patent: WO 93/17670 (1993-09-01), None
patent: WO 9317017 (1993-09-01), None
patent: WO 9418196 (1994-08-01), None
patent: WO 9533729 (1995-12-01), None
patent: WO 9703071 (1997-01-01), None
patent: WO 9945906 (1999-09-01), None
patent: WO 0029397 (2000-05-01), None
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, 1999.
Bonifati V et al: “Buspirone in Levodopa-Induced Dyskinesias” Clinical Neuropharmacology, Raven Press, New York, NY, US, vol. 17, No. 1, 1994, pp. 73-82, XP001087558 ISSN: 0362-5664.
English Abstract of DE 196 48 384.
Luescher et al., Stereotypic or Obsessive-Compulsive Disorders in Dogs and Cats, 1991, Veterinary Clinics of North America. Small Animal Practice, 21(2), pp. 401-413.
Bartoszyk et al., Pharmacological Profile of EMD 128130: A Putative Atypical Antipsychotic with DA D2 Antagoinistic and Serotonin 5-HT1A Agonistic Properties, 1997, Soc. Neurosci. Abstr., 23, p. 530 (#207.5).
Bottcher et al., SAR for Novel Chromanes: Atypical Neuroleptics with 5HT1A Agonistic and D2 Antagonistic Activity, 1996, Soc. Neurosci. Abstr., 22, p. 841 (#334.1).
Brotchie et al., Levodopa-induced dyskinesia in Parkinson's disease, Journal of Neural Transmission, J Neural Transm (2005) 112: 359-391.
Seyfried et al., Biochemical and functional studies on EMD 49 980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems, European Journal of Pharmacology, 160 (1989) 31-41.
Hofmeyr, J.M.: The use of haloperidol as a long-acting neuroleptic in game capture operations, J.S. Afr. Vet. Assoc. 52:273-282, 1981.
Pub Med ID 7857027, 1994.
Overall K L, “Animal Behavior Case of the Month,” Journal of the American Veterinary Medical Association, XX, XX, Sep. 1, 1994, pp. 694-696, vol. 5, No. 205, XP008001693, ISSN: 0003-1488, cited in the application, p. 495, right-hand column, paragraphs 2,3.
Griebel G. et al., “5-HT1A Agonists Modulate Mouse Antipredator Defensive Behavior Differently from the 5-HT2A Antagonist Pirenperone,” Pharmacol. Biochem. Behav., 1995, pp. 235-244, vol. 51, No. 2-3, XP002197804, cited in the application, p. 242, p. 241, right-hand column, paragraph 1-paragraph 3, p. 241, left-hand column, last paragraph, p. 236, left-hand column, paragraph 2.
Bartoszyk G D et al., “Pharmacological Profile of EMD 128130: A Putative Atypical Antipsychotic with Dopamine D2 Antagonistic and Serotonin 5-HT1A Angonistic Properties,” Society for Neuroscience Abstracts, Oct. 25, 1997, p. 530, vol. 23, No. 1/2, XP001066595, ISSN: 0190-5295, abstract 207.5, Society for Neuroscience, US.
Schlemmer R F et al., “Antagonism of Amphetamine-induced Behavior by the Antipshychotic Candidate EMD 77697 in a Primate Social Colony Model for Screening Antipsychotic Agents,” Society for Neuroscience Abstracts, Oct. 25, 1997, p. 1931, vol. 23, No. 1/2, XP001066577, ISSN: 0190-5295; abstract 747.18, Society for Neuroscience, US.
Vliet Van B J et al., “Preclinical Pharmacology of SLV301, a Potent Dopamine D2 Receptor Antagonist and Selective Serotonin Reuptake Inhibitor,” Society for Neuroscience Abstracts, Nov. 4-9, 2000, p. 87116, vol. 26, No. 1/2, XP008001595, ISSN: 0190-5295, abstract, Society for Neuroscience, US.
Liu Y et al., “Derivatives of CIS-2-amino-8-hyroxy-1-Methyltetralin: Mixed 5-HT1A-Receptor Agonists and Dopamine D2-receptor Antagonists,” Journal of Medicinal Chemistry, 1995, pp. 150-160, vol. 1, No. 38, XP001064450, ISSN: 0022-2623, the whole document, American Chemical society, Washington, US.
Joechle W, Fehlverhalten Und Anpassungsprobleme Bei Hund Und Katze Und Deren Pharmakologische Beeinflussbarkeit//Abnormal Behavior and Adaptation Problems and their Pharmacological Control in Dogs and Cats, Tieraerztliche Praxis, Nov. 1998, pp. 410-421, vol. 6, No. 26, XP008001694, ISSN: 0303-6286, the whole document, Schattauer, DE.
Database Biosis ′Online!, Biosciences Information Service, STN AN= 1995:131485, XP002197805, Abstract, Philadelphia, PA, US; & Molewijk et al., “Conditioned ultrasonic distress vocalizations in adult male rats as a behavioral paradigm for screening antipanic drugs,” Psychopharmacology, 1995, pp. 32-40, vol. 117, No. 1, abstract.
Database Drugnl ′Online!, STN AN=97:3859, XP002197806, abstract, & R&D Focus Drug News, Mar. 11, 1997, abstract.
Kleven M et al., “Role of 5-HT1A Receptors in the Ability of Mixed 5-HT1A Receptor Agonist/Dopamine D2 Receptor Antagonists to Inhibit Methylphenidate-induced Behaviors in Rats,” European Journal of Pharmacology, Oct. 10, 1996, pp. 25-34, vol. 313, No. 1/2, XP001066337, ISSN: 0014-2999, Abstract, Amsterdam, NL, p. 26, left-hand column -right-hand column, paragraph 1, p. 29-p. 32.
Prog Neuropsychopharmacol Biol Psychiat (in press), The Effect of Chronic Administration of Sarizotan, 5-HT1Agonist/D3/4 Ligand on Haloperidol Induced Repetitive Jaw Movements in Rat Model of Tardive Dyskinesia, Helen Rosengarten et al., pp. 1-21.
Research Article—Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease, William Bara-Jimenez et al., pp. 1-5.
Psychopharmacology © Springer-Verlag 2005—Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers, Heike E. Kuenzel et al., pp. 1-11.
Journal of Psychopharmacology—16(3) (2002) 195-199—Evaluation of EMD 128 130 occupancy of the 5-HT1Aand the D2receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride, Eugenii A. Rabiner et al., pp. 195-199.
Clin Neuropharmacol—vol. 27, No. 2, Mar.-Apr. 2004, Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients WIth Levodopa-Induced Dyskinesias (the SPLENDID Study), C. Warren Olanow et al., pp. 58-62.
J Neural Transm (2004) 111: 113-126— Sarizotan, a serotonin 5-HT1Areceptor agonist and dopamine receptor ligand. 1. Neurochemcial profile, G. D. Bartoszyk et al., pp. 113-126.
Neuropharmacology 45 (2003) 1057-1069—Contribution of the serotonin 5-HT1Areceptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. E.Lorenc-Koci et al., pp. 1057-1069.
Soc. Neurosci. Abstr., vol. 23, Part 1, p. 530, 1997—209.5 Pharmacological Profile of EMD 128130: A Putative Atypical Antipsychotic With Dopamine D2Antagonistic and Serotonin 5-HT1AAgonistic Properties, G.D. Banoezyk et al.
Soc. Neurosci. Abstr., vol. 22, Part 2, p. 841, 1996, 234.1—SAR for Novel Chromanes: Atypical Neuroleptics With 5HT1A Agonistic and D2 Antagonistic Activity, H. Bottcher et a
Bartoszyk Gerd
Russ Hermann
Seyfried Christoph
Weber Frank
Kantamneni Shobha
Merck Patent Gesellschaft mit beschrankter Haftung
Millen White Zelano & Branigan P.C.
Padmanabhan Sreeni
LandOfFree
Use of(R)-(−)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of(R)-(−)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of(R)-(−)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719274